financetom
Business
financetom
/
Business
/
Forum Energy Q2 revenue beats expectations, raises cash flow guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Forum Energy Q2 revenue beats expectations, raises cash flow guidance
Aug 7, 2025 2:02 PM

Overview

* Forum Energy ( FET ) Q2 rev rises 3% sequentially, beating analyst expectations

* Net income for Q2 at $8 mln, or $0.61 per diluted share

* Co raises full-year free cash flow guidance

Outlook

* Forum Energy ( FET ) raises 2025 free cash flow guidance to $60-$80 mln

* Company expects Q3 adjusted EBITDA between $19 mln and $23 mln

* Forum Energy ( FET ) forecasts full-year adjusted EBITDA of approximately $85 mln

* Strong backlog supports financial outlook despite industry slowdown

Result Drivers

* STRONG BOOKINGS - Offshore defense bookings pushed backlog to highest level in over ten years

* COST SAVINGS - Cost-saving initiatives and tariff mitigation efforts support adjusted EBITDA forecast

* DEMAND VARIATION - Increased demand for coiled line pipe and drilling equipment offset by lower completions-related equipment demand

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $199.80 $190.30

Revenue mln mln (2

Analysts

)

Q2 Net $7.70

Income mln

Q2 Gross $59.40

Profit mln

Q2 $44.70

Operatin mln

g

Expenses

Q2 $14.70

Operatin mln

g Income

Q2 $13.90

Pretax mln

Profit

Analyst Coverage

* Wall Street's median 12-month price target for Forum Energy Technologies Inc ( FET ) is $24.00, about 22% above its August 6 closing price of $18.72

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
United Microelectronics Posts Lower Net Sales in May
United Microelectronics Posts Lower Net Sales in May
Jun 5, 2025
04:38 AM EDT, 06/05/2025 (MT Newswires) -- United Microelectronics ( UMC ) said Thursday its net sales were 19.48 billion New Taiwan dollars ($650.6 million) in May, down 0.2% from a year earlier. For the five months through May, the company's net sales rose 4.2% year over year to NT$97.79 billion. ...
Gamers line up for Nintendo Switch 2 on launch day
Gamers line up for Nintendo Switch 2 on launch day
Jun 5, 2025
* There is pent-up demand for more powerful gaming device * Company has pledged to strengthen production capacity * Switch 2 sales to pass 100 million in 2030 - research firm (Updates with closing share price in paragraph 17) By Sam Nussey and Tom Bateman TOKYO, June 5 (Reuters) - Gaming fans queued up for the launch of Nintendo's (...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Hutchmed, Innovent Biologics Say China Accepts Kidney Cancer Drug Combo Application for Review
Hutchmed, Innovent Biologics Say China Accepts Kidney Cancer Drug Combo Application for Review
Jun 5, 2025
04:33 AM EDT, 06/05/2025 (MT Newswires) -- Hutchmed ( HCM ) and Innovent Biologics said late Wednesday a new drug application for the combination of fruquintinib and sintilimab as a treatment for certain patients with locally advanced or metastatic renal cell carcinoma has been accepted for review by the China National Medical Products Administration. The application is backed by data...
Copyright 2023-2026 - www.financetom.com All Rights Reserved